Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
30 juil. 2021 08h00 HE
|
Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
28 juil. 2021 08h00 HE
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and...
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
24 juin 2021 08h00 HE
|
Optinose, Inc.
YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
05 mai 2021 07h00 HE
|
Optinose, Inc.
Company reports first quarter total revenue of $12.0 million First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020 Conference call and webcast to be...
Optinose to Present at the Needham Virtual Healthcare Conference
12 avr. 2021 16h15 HE
|
Optinose, Inc.
YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
27 févr. 2018 07h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Expands Leadership Team with Key Hires
30 oct. 2017 08h00 HE
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced the addition of five key...